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Background: The plaque reduction neutralization test (PRNT) is currently the best and most widely accepted approach
to measuring virus-neutralizing and protective antibodies to dengue virus, and in assessing the immunogenicity of a
dengue vaccine. However, the correlation between presence of dengue-neutralizing antibody and protection from
infection is not absolute.
Findings: In a cohort study in Ratchaburi Province, Thailand, 48 subjects with serologically confirmed symptomatic
dengue infection were tested for pre-existing dengue neutralizing antibody using PRNT. Nine subjects had quite high
pre-existing PRNT50 titers (titer >90) to subsequent infecting dengue serotypes, but still had symptomatic infections.
Conclusion: This report provides evidence that PRNT may not be a good test for predicting protection against
subsequent dengue infection.
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Background
The plaque reduction neutralization test (PRNT) is a
method for measuring antibodies that neutralize and
prevent virions from infecting cultured cells. It is cur-
rently the most virus-specific serological test among the
flaviviruses, and serotype-specific test among the dengue
viruses [1]. PRNT has been widely used in assessing the
protective neutralizing antibody response for Japanese-
encephalitis vaccines [2-4].
For dengue, PRNT is the best and most widely accepted
approach to measuring virus-neutralizing and protective
antibodies [1], and assessing the immunogenicity of den-
gue vaccine [5-8]. However, the correlation between the
presence of virus-neutralizing antibody and protection
from infection is not absolute. This report aims to provide
additional data on the correlation of pre-existing dengue-
neutralizing antibody and protection from subsequent
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In the cohort study conducted among school children in
Ratchaburi Province, Thailand [9], we prospectively col-
lected serum samples annually from all subjects. Acute
and convalescent serum samples were also collected
from each febrile subject, irrespective of clinical diagnosis.
Clinical diagnosis was performed by a pediatrician who
was unaware of the dengue diagnostic test results. Clinical
diagnoses of dengue fever (DF), dengue hemorrhagic fever
(DHF), and DHF severity were made using the WHO
criteria (1997) [10]. All blood samples were drawn into
serum separator tubes, allowed to clot at room
temperature for 1–2 hours, then stored at 4°C. Sera
were separated into aliquots within 24 hours and stored
at −70°C until laboratory testing. Dengue diagnostic test-
ing was performed at the Center for Vaccine Development,
Institute of Molecular Biosciences, Mahidol University,
Salaya, Nakhonpathom, Thailand (CVD). Acute and con-
valescent sera were tested for dengue-virus-specific IgM/
IgG by enzyme-linked immunosorbent assay (ELISA)
using slightly modified method from that described previ-
ously [11]. The sensitivity of this test was 97% in paired
sera [11]. An IgM anti-dengue level ≥ 1 unit in acute
serum, or seroconversion of either IgM or IgG in pairedentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Primary dengue infection was diagnosed when the IgM:
IgG ratio was >1:1.8. Serum samples from acute dengue
cases were tested for dengue-virus serotype by inoculation
into Toxorhynchites splendens mosquitoes with immuno-
fluorescence detection and serotyping [12].
We randomly selected 48 subjects with acute dengue
infection in the year 2006. Pre-infection sera were re-
trieved from the previous annual serum samples and
tested for pre-existing dengue- and Japanese encephalitis-
neutralizing antibody using PRNT, as described by Russell
et al. [13]. In the tests, conducted at the CVD, monkey
kidney-derived LLC-MK2 cells were used for virus pro-
duction and PRNT. The dengue viruses (D) used in the
assay were D1 (16007), D2 (16681), D3 (16562), and D4
(1036). LLC-MK2 cells were seeded in 6-well plates at
1 × 105 cells/well, and incubated for 6–8 days. Neutral-
izing sera were diluted to 1:5, followed by ten-fold
serial dilutions using phosphate buffer solution (PBS)




PRNT50 titer (Feb 2006)
D1 D2 D3 D4 JE
03-146 <10 <10 <10 <10 155
05-119 <10 <10 <10 <10 235
05-181 <10 <10 <10 <10 <10
05-310 10 <10 167 <10 250
07-479 <10 <10 <10 <10 29
07-383 13 <10 <10 <10 <10
04-276 13 <10 <10 <10 <10
05-357 40 29 27 <10 303
05-002 50 <10 <10 <10 396
03-097 75 1134 24 20 1307
05-339 <10 <10 <10 <10 503
04-322 17 <10 <10 <10 165
04-325 <10 <10 <10 <10 685
02-189 <10 10 12 <10 <10
01-227 49 <10 <10 <10 590
01-254 12450 3348 32 <10 78
01-384 <10 <10 <10 <10 92
06-164 210 540 12040 21 76
01-124 228 135 516 39 28
05-257 3141 194 272 41 726
01-224 195 2901 220 50 802
05-378 6238 2204 676 75 43
aELISA result showed either primary or secondary infection.
AGE: acute gastroenteritis; D: dengue virus; DF: dengue fever; DHF: dengue hemo
reduction neutralization.(for a final starting dilution of 1:10), and incubated. Fol-
lowing infection, cells were overlaid with 3.0% carboxy-
methyl cellulose with neutral red added. Plaques were
visualized and counted after cultivation for 7 days. Data
were interpreted using the Probit model with the SPSS
program, and PRNT endpoint titers were expressed as
the reciprocal of the last serum dilution. The PRNT
titer was calculated based on a 50% reduction in plaque
count (PRNT50).Results
Tables 1, 2, 3 show the pre-existing dengue PRNT50
titers in the sera of subjects in February 2006, date of
subsequent dengue illness, clinical diagnosis, and the
serotype isolated. Among 48 subjects with serologically
confirmed dengue infection, dengue viruses could be
identified in 31 (64.6%) subjects, comprising 16 D1; 1
D2; 3 D3; and 11 D4. Only 5 (10.4%) subjects had pri-









11/10/2006 DF Secondary D1
9/6/2006 Pharyngitis Secondary D1
21/8/2006 DF Primary D1
21/4/2006 DF Secondary D1
23/7/2006 DF Secondary D1
10/9/2006 DF Primary D1
13/3/2006 DF Primary D1
10/10/2006 Bronchitis Secondary D1
25/11/2006 DF Secondary D1
7/10/2006 DF Secondary D1
28/8/2006 Pharyngitis Secondary D2
9/11/2006 DF Secondary D3
23/10/2006 DHF gr2 Secondary D3
6/7/2006 DF Primary D3
19/2/2006 Pharyngitis Secondary D4
28/2/2006 AGE Secondary D4
19/12/2006 Pharyngitis Secondary D4
30/8/2006 DF Secondary D4
31/3/2006 DF Secondary D4
15/10/2006 Common cold Secondary D4
9/3/2006 DHF gr1 Secondary D4
28/7/2006 DF Secondary D4
rrhagic fever; gr: grade; JE: Japanese encephalitis virus; PRNT50: 50% plaque











isolatedD1 D2 D3 D4 JE
06-043 121 224 83 <10 11 14/8/2006 DF Secondary D1
05-021 133 <10 <10 <10 72 26/4/2006 DF Secondary D1
05-074 173 1136 73 31 503 9/5/2006 DF Secondary D1
06-082 317 <10 18 <10 760 14/6/2006 Viral infection Secondary D1
01-286 581 <10 <10 <10 <10 19/4/2006 DF Secondary D1
01-141 1848 821 4521 328 738 6/11/2006 Pharyngitis Secondary D1
07-119 5291 84 332 98 207 28/7/2006 DF Secondary D4
05-244 4916 1305 1006 145 393 21/9/2006 DF Secondary D4
04-378 11682 853 417 261 5615 5/7/2006 DF Secondary D4
aELISA result showed either primary or secondary infection.
D: dengue virus; DF: dengue fever; JE: Japanese encephalitis virus; PRNT50: 50% plaque reduction neutralization.
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identified, 14 (45.2%) had pre-existing PRNT50 titers to
the infecting serotype < 20. Eight subjects (25.8%) had
pre-existing PRNT50 titers to the infecting serotype of
between 21 and 75 (Table 1).
Interestingly, nine (29.0%) subjects had pre-existing
PRNT50 titers of > 90 to the subsequent infecting sero-
types. Six subjects with D1 infections had pre-existing
PRNT50 titers to D1, which ranged from 121 to 1848;Table 3 Pre-existing PRNT50 titer and subsequent dengue inf
serotypes could not be identified
Subject
code
PRNT50 titer (Feb 2006)
D1 D2 D3 D4
01-177 537 218 619 74
01-437 473 297 1283 <10
01-456 14105 2851 7872 235
01-559 393 1606 249 65
02-246 <10 <10 16 <10
02-434 <10 <10 <10 <10
02-453 172 2053 126 53
03-021 867 <10 1026 <10
05-072 351 36 <10 174
05-0112 <10 <10 <10 <10
05-209 310 48 753 14
05-239 3257 8199 111 40
05-358 249 247 3934 34
06-070 236 2687 10649 <10
06-124 472 5074 3943 29
06-192 10 <10 <10 <10
07-310 137 43 23 198
aThe ELISA result showed either primary or secondary infection.
D: dengue virus; DF: dengue fever; DHF: dengue hemorrhagic fever; gr: grade; JE: Jageometric mean value 313; median value 245. Two sub-
jects (subjects 01–286 and 05–021) had PRNT50 pro-
files suggesting previous primary D1 infection, but had
secondary symptomatic infections with the same sero-
type. Three subjects with D4 infections had pre-existing
PRNT50 titers to D4, ranging between 98 to 261, geo-
metric mean value 154 (Table 2).
It is worth noting that many subjects (e.g. subjects







14 1/6/2006 Pharyngitis Secondary
75 9/9/2006 Influenza Secondary
594 27/6/2006 DF Secondary
4987 14/8/2006 viral infection Secondary
2201 3/5/2006 DF Secondary
1326 31/3/2006 Pharyngitis Secondary
14587 10/3/2006 DHF gr3 Secondary
<10 29/11/2006 DHF gr1 Secondary
140 1/12/2006 Viral infection Secondary
<10 2/12/2006 URI Primary
76 29/7/2006 DHF gr1 Secondary
919 24/4/2006 DHF gr1 Secondary
267 10/6/2006 Viral infection Secondary
94 16/6/2006 Pharyngitis Secondary
164 27/8/2006 DHF gr1 Secondary
42 26/8/2006 Pharyngitis Secondary
21 7/8/2006 Influenza Secondary
panese encephalitis virus; PRNT50: 50% plaque reduction neutralization.
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symptomatic infections, which were probably tertiary
infections (Tables 3 and 2, respectively).
Discussion
Dengue viruses comprise 4 serotypes. Infection with one
dengue serotype elicits lifelong homotypic immunity,
but only short-lived immunity for heterotypic serotypes
[14]. Dengue neutralizing antibody has been believed to
represent protection against dengue, and the PRNT test
has been widely used to measure this neutralizing anti-
body. Numerous vaccine immunogenicity assessment la-
boratories consider a seropositive threshold to be 10 [1]
and since four of the subjects in this report had PRNT50
titers of 10–13, we arbitrarily divided the subjects into 3
groups, i.e. titer <20, 20–90, and >90. We found that 17
(54.8%) and 9 (29.0%) of 31 subjects had pre-existing
PRNT50 titers >20 and >90, respectively, to the subse-
quent infecting dengue serotype. These data provide par-
tial insight into the correlation between PRNT50 titer
and disease protection. This is very important, because
PRNT titer is considered an important marker of protec-
tion in the development of dengue vaccines. These data
are perhaps the most relevant available data, as more
valid data on the correlation between pre-existing
PRNT50 titer and disease protection in humans requires
human challenge with dengue virus, which may not be
possible due to ethical issues. This report raises some in-
consistencies with our previous understandings. First,
the finding in 2 subjects (subjects 01–286 and 05–021
[Table 2]) suggests that previous D1 infection may not
induce protection to subsequent symptomatic homoty-
pic dengue infection. Second, a quite high pre-existing
PRNT50 titer (>90) may not be able to protect against
subsequent symptomatic infection from the respective
dengue serotype.
In a cohort study in Thailand, Endy et al. [15] also
found that pre-existing neutralizing antibody directed
against infecting dengue serotype (titer >10) was detected
in 36%, 67%, and 46% of D3, D2, and D1 infections, re-
spectively. Moreover, only a pre-existing PRNT50 > 100
against the reference D3 strain was associated with milder
severity of disease, but not in D2 and D1. This is further
confirmed by the finding in a phase-2b dengue-vaccine
trial among Thai children that the tetravalent live-
attenuated dengue vaccine had a low level of efficacy
against D2, despite its high immunogenicity [16].
There are some possible explanations for the lack of a
definite correlation between PRNT50 titer and protec-
tion from subsequent dengue infection. One possible
explanation is that in our PRNT, we used LLC-MK2
cells, which are not FcγR-expressing cells. In the absence
of FcγR, dengue virus-antibody complexes are not able
to infect the cells, while these complexes are taken upmore efficiently by FcγR-expressing cells, and are still
infectious [17]. This is supported by the study of Moi
et al. [18], who found that 11 of 18 serum samples from
patients with acute secondary dengue infection demon-
strated neutralizing activity to the infecting serotype,
determined using FcγR-negative BHK cells, but not
when determined using FcγR-expressing cells. Another
explanation is that the protective PRNT50 titer for den-
gue may be much higher than the titer of 10, defined for
Japanese encephalitis virus, and the protective level of
dengue neutralizing antibody should be more accurately
defined. This study revealed that subjects with pre-
existing PRNT50 titer of up to 1848 against D1, and 261
against D4, still had symptomatic infections due to the
respective serotypes, suggesting the protective level
should be higher and may differ for different serotypes.
Nevertheless, defining the protective-level cut-off point
is difficult and challenging. A very large cohort study
and long-term follow-up are needed, unless a challenge
test in subjects with pre-defined PRNT levels could be
conducted. Moreover, as PRNT titers vary significantly
depending on testing conditions, such as virus strains,
virus passage and cell type [19,20], optimal testing
conditions should be defined.
Finally, the pre-infection PRNT50 titers are against
reference dengue-virus strains. As molecular evolution
among dengue viruses has been continuous [21], it may
cause antigenic mismatches between the reference den-
gue virus strains used in the PRNT and infecting viruses,
and therefore, mismatch between the pre-existing antibody
and the antigen of the infecting homologous serotype.
Further studies are needed to clarify these possibilities.
It is also noted that dengue-naïve but Japanese
encephalitis (JE)-immuned subjects shown by PRNT
(e.g. subjects 01–384, 04–325, 07–479) showed secondary
antibody response to subsequent dengue infection. One
subject (subject 04–325) had DHF grade2. These pieces
of evidence suggest cross-reactive antibody responses
between dengue and JE.Competing interests
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